BLA 761139 · Daiichi Sankyo
Enhertu
Fam-Trastuzumab Deruxtecan-Nxki · Injection
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: May 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Dec 20, 2019
Approved uses
14
Original approval plus efficacy supplements
Registered trials
27
2 Phase 3, 20 recruiting
FAERS reports
10,910
8,277 serious, 2,791 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY Interstitial Lung Disease (ILD) and pneumonitis, including severe, life-threatening, and fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and the need to immediately report symptoms [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) ] . Embryo-Fetal Toxicity: Exposure to ENHERTU during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception [see Warnings and Precautions (5.4) , Use in Specific Populations (8.1 , 8.3) ] . WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY See full prescribing...
What it is approved for
From the label in effect May 15, 2026.
ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for: HER2-Positive Early Breast Cancer as neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test followed by a taxane, trastuzumab, and pertuzumab (THP). ( 1.1 ) as adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment. ( 1.1 ) HER2-Positive Metastatic Breast Cancer in combination with pertuzumab as first-line treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer, as determined by an FDA-authorized test. ( 1.2 ) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or, in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. ( 1.2 ) HER2-Low and HER2-Ultralow Metastatic Breast Cancer as monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-authorized test, that has progressed on one or more endocrine therapies in the metastatic setting. ( 1.3 ) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-authorized test, who have received a prior chemotherapy in the metastatic setting; or developed...
Mechanism: Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody-drug conjugate. The antibody is a humanized anti-HER2 IgG1. The small molecule, DXd, is a topoisomerase I inhibitor attached to the antibody by a cleavable linker. Following binding to HER2 on tumor cells, fam-trastuzumab deruxtecan-nxki undergoes internalization and intracellular linker cleavage by lysosomal enzymes. Upon release, the membrane-permeable DXd causes DNA damage and apoptotic cell death.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 15, 2026 Supplement 43 · Efficacy · priority review Breakthrough therapyOrphanLetterLabelMedication Guide
- May 15, 2026 Supplement 41 · Efficacy OrphanLetterLabelMedication Guide
- Apr 27, 2026 Supplement 39 · Efficacy OrphanLabelLetter
- Dec 15, 2025 Supplement 38 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Jan 27, 2025 Supplement 32 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Apr 5, 2024 Supplement 28 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
- Feb 15, 2024 Supplement 26 · Efficacy OrphanLabelLetter
- Nov 4, 2022 Supplement 24 · Efficacy · priority review LabelLetter
- Aug 11, 2022 Supplement 21 · Efficacy · priority review Breakthrough therapyLabelLetterReview
- Aug 5, 2022 Supplement 22 · Efficacy · priority review Breakthrough therapyLetterLabel
- May 4, 2022 Supplement 20 · Efficacy · priority review Breakthrough therapyLabelLetter
- May 4, 2022 Supplement 17 · Efficacy · priority review LabelLetter
- Jan 15, 2021 Supplement 11 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
- Dec 20, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
1 products under this application
- ENHERTU · FAM-TRASTUZUMAB DERUXTECAN-NXKI 100MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fam-Trastuzumab Deruxtecan" as an intervention, any sponsor and status, largest first.
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
- Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT07578116 · 562 participants (planned) · Start Mar 9, 2027 · Primary completion May 31, 2032
Drug: Cyclin-Dependent Kinase 4 Inhibitor; Cyclin-Dependent Kinase 6 Inhibitor and 7 more · For: Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma; Oligometastatic Breast Carcinoma
Sites: Jonesboro, Arkansas; Derby, Connecticut; Fairfield, Connecticut · 59 sites in all
- A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04739761 · 506 participants · Start Jun 22, 2021 · Primary completion Feb 8, 2024
Drug: Trastuzumab Deruxtecan · For: Breast Cancer
Sites: Boston, Massachusetts; Durham, North Carolina; Adelaide, Australia · 81 sites in all
National Cancer Institute (NCI)NIH
NCT06311214 · 500 participants (planned) · Start Mar 18, 2025 · Primary completion Mar 31, 2028
Drug: Enfortumab Vedotin; Sacituzumab Govitecan and 1 more · For: Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm
Sites: Duarte, California; Encinitas, California; Irvine, California · 29 sites in all
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT05868226 · 280 participants (planned) · Start Feb 15, 2023 · Primary completion Dec 30, 2030
Drug: ALX148; Fam-Trastuzumab Deruxtecan-Nxki and 3 more · For: HER2-positive Breast Cancer; Metastatic Cancer; Metastatic Breast Cancer and 29 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Aurora, Colorado · 10 sites in all
- ELVN-002 in HER2 Mutant Non-Small Cell Lung CancerActive, not recruiting
Enliven TherapeuticsIndustry
NCT05650879 · 198 participants (planned) · Start Mar 20, 2023 · Primary completion Jul 2026
Drug: ELVN-002; Fam-Trastuzumab Deruxtecan-Nxki and 1 more · For: HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer; HER2 Gene Mutation and 1 more
Sites: Aurora, Colorado; Orlando, Florida; Plantation, Florida · 39 sites in all
NRG OncologyAcademic, hospital or other
NCT05408845 · 146 participants (planned) · Start Mar 3, 2023 · Primary completion Jul 31, 2028
Drug: Docetaxel; Trastuzumab and 2 more · For: Metastatic Salivary Gland Carcinoma; Recurrent Salivary Gland Carcinoma; Stage III Major Salivary Gland Cancer AJCC v8 and 2 more
Sites: Birmingham, Alabama; Duarte, California; Dublin, California · 154 sites in all
Jonsson Comprehensive Cancer CenterAcademic, hospital or other
NCT04553770 · 88 participants (planned) · Start Oct 9, 2020 · Primary completion Dec 31, 2026
Drug: Anastrozole; Trastuzumab Deruxtecan · For: Early-stage Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Invasive Breast Cancer and 4 more
Sites: Fullerton, California; Los Alamitos, California; Los Angeles, California · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death1,336
- nausea1,288
- disease progression1,257
- interstitial lung disease1,100
- fatigue858
- off label use846
- diarrhoea632
- vomiting593
- pneumonitis441
- decreased appetite410
- asthenia407
- no adverse event381
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2019 | 4 |
| 2020 | 380 |
| 2021 | 717 |
| 2022 | 1,274 |
| 2023 | 1,808 |
| 2024 | 2,028 |
| 2025 | 2,248 |
| 2026 | 2,450 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Enhertu (Fam-Trastuzumab Deruxtecn-Nxki)
2024 spending
$10.6M
Beneficiaries
171
1,011 claims
Per beneficiary
$62,221
$2,588.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,410,930 |
| 2021 | $3,350,096 |
| 2022 | $4,311,977 |
| 2023 | $10,228,153 |
| 2024 | $10,639,779 |
Part B: Enhertu (Fam-Trastuzumab Deruxtecn-Nxki) · HCPCS J9358
2024 spending
$581M
Beneficiaries
8,410
56,172 claims
Per beneficiary
$69,140
2024 ASP limit $27.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $37,181,509 |
| 2021 | $109,118,974 |
| 2022 | $257,875,575 |
| 2023 | $464,747,799 |
| 2024 | $581,465,185 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations.
Mehta GU, Vellanki PJ, Ren Y, et al. · Oncologist 2024 · Multicenter Study, Randomized Controlled Trial
- FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer.
Narayan P, Osgood CL, Singh H, et al. · Clin Cancer Res 2021 · Randomized Controlled Trial
- US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer.
Narayan P, Dilawari A, Osgood C, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Multicenter Study
- An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers.
Shin SH, Park YH, Park SS, et al. · Adv Sci (Weinh) 2021 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: Daiichi Sankyo
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.